论文部分内容阅读
支气管哮喘(简称哮喘)是一种气道的慢性炎症性疾病,严重威胁着人类的健康。目前,其发病率和死亡率呈上升趋势。前不久被誉为“中国飞人”的柯受良死于哮喘。尤其是慢性反复发作过程的患者,给患者及家属以及社会造成极大的经济负担。对此,已引起全世界的极大关注。1993年世界卫生组织(WHO)制订了“全球哮喘防治创议”(GINA),规范哮喘的诊断和治疗。
Bronchial asthma (referred to as asthma) is a chronic inflammatory disease of the airways, a serious threat to human health. At present, its morbidity and mortality are on the rise. Not long ago, Ke Shui-liang, hailed as “the Chinese trapeze,” died of asthma. In particular, patients with chronic recurrent episodes, to patients and their families and the community caused a great financial burden. In this regard, great attention has been drawn worldwide. In 1993, the World Health Organization (WHO) formulated the Global Initiative on Asthma Prevention and Control (GINA) to standardize the diagnosis and treatment of asthma.